<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599571</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00066144</org_study_id>
    <secondary_id>1R01HD083404</secondary_id>
    <nct_id>NCT02599571</nct_id>
  </id_info>
  <brief_title>Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers</brief_title>
  <acronym>ADHDenic</acronym>
  <official_title>Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the impact of different nicotine levels in&#xD;
      cigarettes with individuals who have ADHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine the effects of very low nicotine content (VLNC)&#xD;
      cigarettes on smoking behavior, psychiatric symptoms and functioning, and acceptability and&#xD;
      adverse outcomes in young adult smokers with ADHD. Participants will attend a screening&#xD;
      session, 2 baseline sessions, 6 experimental sessions, and a 30 day follow-up visit.&#xD;
      Participants will be asked to smoke only the study cigarettes that we provide for 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor discontinued funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 30, 2016</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cigarettes smoked per day</measure>
    <time_frame>Six weeks</time_frame>
    <description>Self-reported number of cigarettes smoked per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite measure of influence of reduced nicotine content on ADHD symptoms measured by ADHD Rating Scale and Clinical Global Impressions Scale along with related measures of cognition measured by the N-Back Task and the Continuous Performance Test</measure>
    <time_frame>Six weeks</time_frame>
    <description>Composite of ADHD symptom questionnaires, inhibitory control, working memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite measure of outcomes associated with acceptability; withdrawal measured by the MNWS and compliance measured by Time-Line Follow-Back questionnaire and daily self-report cigarette use</measure>
    <time_frame>Six weeks</time_frame>
    <description>Composite of study dropout, compliance, changes in physical health</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of discomfort/dysfunction; withdrawal and depression</measure>
    <time_frame>Six weeks</time_frame>
    <description>Withdrawal scale and depression measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of other health-related behaviors; dependence measures</measure>
    <time_frame>Six weeks</time_frame>
    <description>Drug and alcohol use questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Very low nicotine content cigarettes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reduced nicotine content cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional nicotine content cigarettes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional nicotine content cigarettes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very low nicotine content cigarettes</intervention_name>
    <description>Cigarettes containing a reduced amount of nicotine</description>
    <arm_group_label>Conventional nicotine content cigarettes</arm_group_label>
    <arm_group_label>Very low nicotine content cigarettes</arm_group_label>
    <other_name>Tobacco</other_name>
    <other_name>Cigarettes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional nicotine content cigarettes</intervention_name>
    <description>Cigarettes containing a normal amount of nicotine</description>
    <arm_group_label>Conventional nicotine content cigarettes</arm_group_label>
    <arm_group_label>Very low nicotine content cigarettes</arm_group_label>
    <other_name>Tobacco</other_name>
    <other_name>Cigarettes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 40&#xD;
&#xD;
          -  Smoke an average of 5-40 cigarettes per day for at least 1 year&#xD;
&#xD;
          -  Breath CO levels &gt; 8 ppm (if â‰¤ 8 ppm, then NicAlert Strip &gt; 6)&#xD;
&#xD;
          -  Primary diagnosis of ADHD, any subtype as assessed by the CAADID; T-Score &gt; 65 on one&#xD;
             of the DSM- V relevant scales (Inattentive Symptoms, Hyperactive-Impulsive Symptoms,&#xD;
             Total Symptoms or ADHD Index) on the Self-Report version of the CAARS; Clinician Rated&#xD;
             ADHD-RS score &gt;24.&#xD;
&#xD;
          -  Cognitive functioning &gt; 80 as assessed by the KBIT-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intention to quit smoking in the next 30 days&#xD;
&#xD;
          -  Currently seeking treatment for smoking cessation&#xD;
&#xD;
          -  Currently using nicotine replacement therapies or other pharmacotherapies as cessation&#xD;
             aid (intermittent use acceptable)&#xD;
&#xD;
          -  A quit attempt in the past 30 days resulting in greater than 3 days of abstinence&#xD;
&#xD;
          -  Using other tobacco products more than 9 days in the past 30 days&#xD;
&#xD;
          -  Significant unstable medical conditions (any significant change in a serious medical&#xD;
             condition occurring during the past 3 months including cardiovascular disease, COPD,&#xD;
             and cancer, as determined by the study physician at each site)&#xD;
&#xD;
          -  Significant unstable psychiatric conditions (any significant change in psychiatric&#xD;
             symptoms during the past 3 months as determined by the study physician at each site)&#xD;
&#xD;
          -  Any Axis I Psychiatric Disorder as assessed by the MINI that is significantly&#xD;
             impairing and/or would contraindicate participation in the study&#xD;
&#xD;
          -  Psychiatric medication changes in the past 3 months including new prescriptions,&#xD;
             changes in dosages or discontinuation of medications&#xD;
&#xD;
          -  Positive toxicology screen for any of the following drugs: cocaine, opiates,&#xD;
             methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP&#xD;
             (Marijuana will be tested for but will not be an exclusionary criterion, participants&#xD;
             with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or&#xD;
             methadone will not be excluded, participants failing the toxicology screen will be&#xD;
             allowed to re-screen once. These participants will need to be re-consented before&#xD;
             being rescreened to ensure they have received adequate informed consent.)&#xD;
&#xD;
          -  Breath alcohol level &gt; 0.01 (Participants failing the breath alcohol screen will be&#xD;
             allowed to re-screen once. These participants will need to be re-consented before&#xD;
             being rescreened to ensure they have received adequate informed consent.)&#xD;
&#xD;
          -  Current diagnosis of DSM alcohol or drug use disorder (except for nicotine)&#xD;
&#xD;
          -  Pregnant, trying to become pregnant or breastfeeding&#xD;
&#xD;
          -  Smoking 'roll your own cigarettes' exclusively&#xD;
&#xD;
          -  Currently taking anticonvulsant medications including: Phenytoin [Brand Name:&#xD;
             Dilantin], Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol],&#xD;
             Oxcarbazepine [Brand Name: Trileptal], Primidone [Brand Name: Mysoline], Phenobarbital&#xD;
&#xD;
          -  CO reading &gt;80 ppm&#xD;
&#xD;
          -  Systolic BP between 90 and 160 (If below 90 then asymptomatic. Participants failing&#xD;
             for blood pressure will be allowed to re-screen once.)&#xD;
&#xD;
          -  Diastolic BP between 50 and 100 (If below 50 then asymptomatic. Participants failing&#xD;
             for blood pressure will be allowed to re-screen once.)&#xD;
&#xD;
          -  Heart rate between 45 and 115 bpm (If below 45 then asymptomatic. Participants failing&#xD;
             for heart rate will be allowed to re-screen once.)&#xD;
&#xD;
          -  Indicating any suicidal ideation in the past month or suicide attempts in the past 10&#xD;
             years.&#xD;
&#xD;
          -  Inability to independently read and comprehend the consent form and other written&#xD;
             study materials and measures.&#xD;
&#xD;
          -  Having participated in a research study during the past three months in which the&#xD;
             participant: Smoked a cigarette that was not his/her usual brand cigarette for more&#xD;
             than one day, used any tobacco products beyond normal use for more than one day, used&#xD;
             any nicotine replacement products or smoking cessation medications for more than one&#xD;
             day&#xD;
&#xD;
          -  Any previous experience using SPECTRUM cigarettes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Kollins, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke ADHD Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

